NF-κB in cancer: from innocent bystander to major culprit (original) (raw)

• Ghosh, S., May, M. J. & Kopp, E. B. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225–260 (1998).
  CAS PubMed Google Scholar
• Gilmore, T. D. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 18, 6925–6937 (1999).
  CAS PubMed Google Scholar
• Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621–663 (2000).
  Article CAS PubMed Google Scholar
• Li, Z.-W. et al. The IKKβ subunit of IκB kinase (IKK) is essential for NF-κB activation and prevention of apoptosis. J. Exp. Med. 189, 1839–1845 (1999).
  CAS PubMed PubMed Central Google Scholar
• Solan, N. J., Miyoshi, H., Bren, G. D. & Paya, C. V. RelB cellular regulation and transcriptional activity are regulated by p100. J. Biol. Chem. 277, 1405–1418 (2002).
  CAS PubMed Google Scholar
• Senftleben, U. et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 293, 1495–1499 (2001).
  CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).Shows how IKKα activates a second NF-κB pathway by NF-κB2 processing from p100 to p52 in response to NIK stimulation — a function that is not provided by IKKβ.
  CAS PubMed Google Scholar
• Xiao, G. et al. Retroviral oncoprotein Tax induces processing of NF-κB2/p100 in T cells: evidence for the involvement of IKKα. Oncogene 20, 6805–6815 (2001).
  CAS Google Scholar
• Mosialos, G. The role of Rel/NF-κB proteins in viral oncogenesis and the regulation of viral transcription. Semin. Cancer Biol. 8, 121–129 (1997).
  CAS PubMed Google Scholar
• Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G. & Baldwin, A. S. Jr., NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell Biol. 19, 5785–5799 (1999).
  CAS PubMed PubMed Central Google Scholar
• Hinz, M. et al. NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell Biol. 19, 2690–2698 (1999).
  CAS PubMed PubMed Central Google Scholar
• Cao, Y. et al. IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107, 763–775 (2001).Reports that IKKα kinase activity is required for mammary-gland development during pregnancy, and it is an essential mediator for cyclin D1 induction by NF-κB in response to pregnancy signals.
  CAS PubMed Google Scholar
• Beg, A. A. & Baltimore, D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274, 782–784 (1996).
  CAS PubMed Google Scholar
• Liu, Z.-G., Hu, H., Goeddel, D. V. & Karin, M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis, while NF-κB activation prevents cell death. Cell 87, 565–576 (1996).
  CAS PubMed Google Scholar
• Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R. & Verma, I. M. Suppression of TNFα-induced apoptosis by NF-κB. Science 274, 787–789 (1996).
  Article CAS PubMed Google Scholar
• Wang, C.-Y., Mayo, M. W. & Baldwin, A. S. Jr., TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274, 784–787 (1996).
  CAS PubMed Google Scholar
• Karin, M. & Lin, A. NF-κB at the crossroad of Life and Death. Nature Immunol. 3, 221–227 (2002).
  CAS Google Scholar
• Wang, C. Y., Cusack, J. C. Jr, Liu, R. & Baldwin, A. S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nature Med. 5, 412–417 (1999).NF-κB activation during cancer therapy is the principle mechanism of tumour chemoresistance. This article shows that inhibition of NF-κB sensitizes chemoresistant tumours to apoptosis.
  PubMed Google Scholar
• Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 (1997).
  CAS PubMed Google Scholar
• Webster, G. A. & Perkins, N. D. Transcriptional cross talk between NF-κB and p53. Mol. Cell Biol. 19, 3485–3495 (1999).
  CAS PubMed PubMed Central Google Scholar
• Koch, A. E. et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258, 1798–1801 (1992).
  CAS PubMed Google Scholar
• Takeshita, H. et al. Matrix metalloproteinase 9 expression is induced by Epstein–Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J. Virol. 73, 5548–5555 (1999).
  CAS PubMed PubMed Central Google Scholar
• Wang, W., Abbruzzese, J. L., Evans, D. B. & Chiao, P. J. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 18, 4554–4563 (1999).
  CAS PubMed Google Scholar
• Bond, M., Fabunmi, R. P., Baker, A. H. & Newby, A. C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB. FEBS Lett. 435, 29–34 (1998).
  CAS PubMed Google Scholar
• Huang, S., Robinson, J. B., Deguzman, A., Bucana, C. D. & Fidler, I. J. Blockade of NF-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin-8. Cancer Res. 60, 5334–5339 (2000).
  CAS PubMed Google Scholar
• Houldsworth, J. et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 87, 25–29 (1996).
  CAS PubMed Google Scholar
• Lu, D. et al. Alterations at the rel locus in human lymphoma. Oncogene 6, 1235–1241 (1991).
  CAS PubMed Google Scholar
• Joos, S. et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87, 1571–1578 (1996).
  CAS PubMed Google Scholar
• Kabrun, N., Bumstead, N., Hayman, M. J. & Enrietto, P. J. Characterization of a novel promoter insertion in the c-Rel locus. Mol. Cell Biol. 10, 4788–4794 (1990).
  CAS PubMed PubMed Central Google Scholar
• Gilmore, T. D., Cormier, C., Jean-Jacques, J. & Gapuzan, M. E. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene 20, 7098–7103 (2001).
  CAS PubMed Google Scholar
• Trecca, D. et al. Identification of a tumor-associated mutant form of the NF-κB RelA gene with reduced DNA-binding and transactivating activities. Oncogene 14, 791–799 (1997).
  CAS PubMed Google Scholar
• Neri, A. et al. B-cell lymphoma-associated chromosomal translocation involves candidate oncogene Lyt-10, homologous to NF-κB p50. Cell 67, 1075–1087 (1991).Shows that p50 homologous protein LYT10 is associated with chromosomal translocation in B-cell lymphoma — the first evidence that NF-κB family members have oncogenic potential.
  CAS PubMed Google Scholar
• Neri, A. et al. Molecular analysis of cutaneous B- and T-cell lymphomas. Blood 86, 3160–3172 (1995).
  CAS PubMed Google Scholar
• Migliazza, A. et al. Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/Lyt-10 gene in lymphoid malignancies. Blood 84, 3850–3860 (1994).
  CAS PubMed Google Scholar
• Ishikawa, H., Carrasco, D., Claudio, E., Ryseck, R.-P. & Bravo, R. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J. Exp. Med. 186, 999–1014 (1997).
  CAS PubMed PubMed Central Google Scholar
• Ohno, H., Takimoto, G. & McKeithan, T. W. The candidate proto-oncogene Bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 60, 991–997 (1990).
  CAS PubMed Google Scholar
• Dechend, R. et al. The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators. Oncogene 18, 3316–3323 (1999).
  CAS PubMed Google Scholar
• Caamano, J. H., Perez, P., Lira, S. A. & Bravo, R. Constitutive expression of Bcl-3 in thymocytes increases the DNA binding of NF-κB1 (p50) homodimers in vivo. Mol. Cell Biol. 16, 1342–1348 (1996).
  CAS PubMed PubMed Central Google Scholar
• Ong, S. T. et al. Lymphadenopathy, splenomegaly, and altered immunoglobulin production in Bcl3 transgenic mice. Oncogene 16, 2333–2343 (1998).
  CAS PubMed Google Scholar
• Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).Explains how diffuse large B-cell lymphoma (DLBCL) can be classified into two types on the basis of gene-expression profile, germinal-center-like DLBCL and activated B-cell-like DLBCL.
  CAS PubMed Google Scholar
• Yamaoka, S. et al. Constitutive activation of NF-κB is essential for transformation of rat fibroblasts by the human T-cell leukemia virus type I Tax protein. EMBO J. 15, 873–887 (1996).
  CAS PubMed PubMed Central Google Scholar
• Knecht, H., Berger, C., Rothenberger, S., Odermatt, B. F. & Brousset, P. The role of Epstein–Barr virus in neoplastic transformation. Oncology 60, 289–302 (2001).
  CAS PubMed Google Scholar
• Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M. & Baldwin, A. S. Jr., A requirement for NF-κB activation in Bcr–Abl-mediated transformation. Genes Dev. 12, 968–981 (1998).
  CAS PubMed PubMed Central Google Scholar
• Madry, C. et al. The characterization of murine Bcma gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int. Immunol. 10, 1693–1702 (1998).
  CAS PubMed Google Scholar
• Furman, R. R., Asgary, Z., Mascarenhas, J. O., Liou, H. C. & Schattner, E. J. Modulation of NF-κB activity and apoptosis in chronic lymphocytic leukemia B cells. J. Immunol. 164, 2200–2206 (2000).
  CAS PubMed Google Scholar
• Zucca, E., Roggero, E. & Pileri, S. B-cell lymphoma of MALT type: a review with special emphasis on diagnostic and management problems of low-grade gastric tumours. Br. J. Haematol. 100, 3–14 (1998).
  CAS PubMed Google Scholar
• Willis, T. G. et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96, 35–45 (1999).
  CAS PubMed Google Scholar
• Ruland, J. et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure. Cell 104, 33–42 (2001).
  CAS PubMed Google Scholar
• Akagi, T. et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18, 5785–5794 (1999).
  CAS PubMed Google Scholar
• Lucas, P. C. et al. BCL10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-κB signalling pathway. J. Biol. Chem. 276, 19012–19019 (2001).
  CAS PubMed Google Scholar
• Krappmann, D. et al. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed–Sternberg cells. Oncogene 18, 943–953 (1999).
  CAS PubMed Google Scholar
• Bargou, R. C. et al. Constitutive NF-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100, 2961–2969 (1997).
  CAS PubMed PubMed Central Google Scholar
• Cahir-McFarland, E. D., Davidson, D. M., Schauer, S. L., Duong, J. & Kieff, E. NF-κB inhibition causes spontaneous apoptosis in Epstein–Barr virus-transformed lymphoblastoid cells. Proc. Natl Acad. Sci. USA 97, 6055–6060 (2000).
  CAS PubMed PubMed Central Google Scholar
• Keller, S. A., Schattner, E. J. & Cesarman, E. Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96, 2537–2542 (2000).
  CAS PubMed Google Scholar
• Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K. & Baldwin, A. S. Jr. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for BCL3. Oncogene 19, 1123–1131 (2000).
  CAS PubMed Google Scholar
• Sovak, M. A. et al. Aberrant NF-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100, 2952–2960 (1997).
  CAS PubMed PubMed Central Google Scholar
• Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, J. R. J. & Sledge, J. G. W. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol. Cell Biol. 17, 3629–3639 (1997).
  CAS PubMed PubMed Central Google Scholar
• Kim, D. W. et al. Activation of NF-κB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21, 871–879 (2000).
  PubMed Google Scholar
• Dejardin, E. et al. Highly expressed p100/p52 (NFKB2) sequesters other NF-κB-related proteins in the cytoplasm of human breast cancer cells. Oncogene 11, 1835–1841 (1995).
  CAS PubMed Google Scholar
• Pianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J. & Sonenshein, G. E. Her2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκBα that can be inhibited by the tumor suppressor PTEN. Oncogene 20, 1287–1299 (2001).
  CAS PubMed Google Scholar
• Zhou, B. P. et al. HER2/neu blocks tumor necrosis factor-induced apoptosis via the AKT/NF-κB pathway. J. Biol. Chem. 275, 8027–8031 (2000).
  CAS PubMed Google Scholar
• Finco, T. S. et al. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272, 24113–24116 (1997).
  CAS PubMed Google Scholar
• Hennighausen, L. & Robinson, G. W. Signaling pathways in mammary gland development. Dev. Cell 1, 467–475 (2001).
  CAS PubMed Google Scholar
• Clarkson, R. W. et al. NF-κB inhibits apoptosis in murine mammary epithelia. J. Biol. Chem. 275, 12737–12742 (2000).
  CAS PubMed Google Scholar
• Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41–50 (2000).Shows that TNF family member RANKL is required for mammary-gland development during pregnancy, and the receptor for RANKL, RANK, phenocopies the defect.
  CAS PubMed Google Scholar
• Fantl, V., Stamp, G., Andrews, A., Rosewell, I. & Dickson, C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9, 2364–2372 (1995).
  CAS PubMed Google Scholar
• Sicinski, P. et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82, 621–630 (1995).
  CAS PubMed Google Scholar
• Albanese, C. et al. Transforming p21Ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270, 23589–23597 (1995).
  CAS PubMed Google Scholar
• Yu, Q., Geng, Y. & Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017–1021 (2001).The RAS and NEU oncogenes depend on cyclin D1 to transform mammary epithelia, whereas MYC and WNT1 oncogenes are independent of it.
  CAS PubMed Google Scholar
• Romieu-Mourez, R. et al. Roles of IKK kinases and protein kinase CK2 in activation of NF-κB in breast cancer. Cancer Res. 61, 3810–3818 (2001).
  CAS PubMed Google Scholar
• Biswas, D. K. et al. The nuclear factor κ-B (NF-κB): a potential therapeutic target for estrogen receptor negative breast cancers. Proc. Natl Acad. Sci. USA 98, 10386–10391 (2001).
  CAS PubMed PubMed Central Google Scholar
• Peek, R. M. J. & Blaser, M. J. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature Rev. Cancer 2, 28–37 (2002).
  CAS Google Scholar
• El-Omar, E. M. et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398–402 (2000).
  CAS PubMed Google Scholar
• Keates, S., Hitti, Y. S., Upton, M. & Kelly, C. P. Helicobacter pylori infection activates NF-κB in gastric epithelial cells. Gastroenterology 113, 1099–1109 (1997).
  CAS PubMed Google Scholar
• Kim, H., Lim, J. W. & Kim, K. H. _Helicobacter pylori_-induced expression of interleukin-8 and cyclooxygenase-2 in AGS gastric epithelial cells: mediation by NF-κB. Scand. J. Gastroenterol. 36, 706–716 (2001).
  CAS PubMed Google Scholar
• Barnes, P. J. & Karin, M. NF-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066–1071 (1997).
  CAS PubMed Google Scholar
• Lind, D. S. et al. NF-κB is upregulated in colorectal cancer. Surgery 130, 363–369 (2001).
  CAS PubMed Google Scholar
• Hardwick, J. C., van den Brink, G. R., Offerhaus, G. J., van Deventer, S. J. & Peppelenbosch, M. P. NF-κB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 20, 819–827 (2001).
  CAS PubMed Google Scholar
• Rustgi, A. K. Hereditary gastrointestinal polyposis and nonpolyposis syndromes. N. Engl. J. Med. 331, 1694–1702 (1994).
  CAS PubMed Google Scholar
• Chung, D. C. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 119, 854–865 (2000).
  CAS PubMed Google Scholar
• Neurath, M. F., Pettersson, S., Meyer zum Buschenfelde, K. H. & Strober, W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nature Med. 2, 998–1004 (1996).NF-κB is activated in a mouse model of human Crohn's disease. Blocking p65 abrogates the signs of colitis.
  CAS PubMed Google Scholar
• Rogler, G. et al. NF-κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115, 357–369 (1998).
  CAS PubMed Google Scholar
• Ekbom, A., Helmick, C., Zack, M. & Adami, H. O. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 336, 357–359 (1990).
  CAS PubMed Google Scholar
• Kühn, R., Lohler, J., Rennick, D., Rajewsky, K. & Müller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 203–205 (1993).
  Google Scholar
• Wahl, C., Liptay, S., Adler, G. & Schmid, R. M. Sulfasalazine: a potent and specific inhibitor of NF-κB. J. Clin. Invest. 101, 1163–1174 (1998).
  CAS PubMed PubMed Central Google Scholar
• Weber, C. K., Liptay, S., Wirth, T., Adler, G. & Schmid, R. M. Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology 119, 1209–1218 (2000).
  CAS PubMed Google Scholar
• Egan, L. J. et al. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J. Biol. Chem. 274, 26448–26453 (1999).
  CAS PubMed Google Scholar
• Majumdar, S. & Aggarwal, B. B. Methotrexate suppresses NF-κB activation through inhibition of IκBα phosphorylation and degradation. J. Immunol. 167, 2911–2920 (2001).
  CAS PubMed Google Scholar
• Eberhart, C. E. et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183–1188 (1994).
  CAS PubMed Google Scholar
• Williams, C. S. et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111, 1134–1140 (1996).
  CAS PubMed Google Scholar
• Taketo, M. M. COX-2 and colon cancer. Inflamm. Res. 47, S112–S116 (1998).
  CAS PubMed Google Scholar
• Oshima, M. et al. Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803–809 (1996).
  CAS PubMed Google Scholar
• Giovannucci, E. et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121, 241–246 (1994).
  CAS PubMed Google Scholar
• Thun, M. J., Namboodiri, M. M. & Heath, C. W. J. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325, 1593–1596 (1991).Frequent aspirin use decreases death rates from colon cancer.
  CAS PubMed Google Scholar
• Rao, C. V., Rivenson, A., Simi, B. & Reddy, B. S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 55, 259–266 (1995).
  CAS PubMed Google Scholar
• Boolbol, S. K. et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56, 2556–2560 (1996).
  CAS PubMed Google Scholar
• Farrow, D. C. et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 7, 97–102 (1998).
  CAS PubMed Google Scholar
• Zaridze, D., Borisova, E., Maximovitch, D. & Chkhikvadze, V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int. J. Cancer 82, 473–476 (1999).
  CAS PubMed Google Scholar
• Yin, M. J., Yamamoto, Y. & Gaynor, R. B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396, 77–80 (1998).Aspirin and sodium salicylate specifically inhibit IKKβ activity — the first evidence that IKK is the direct target of anti-inflammatory agents.
  CAS PubMed Google Scholar
• Yamamoto, Y., Yin, M. J., Lin, K. M. & Gaynor, R. B. Sulindac inhibits activation of the NF-κB pathway. J. Biol. Chem. 274, 27307–27314 (1999).
  CAS PubMed Google Scholar
• Plummer, S. M. et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex. Oncogene 18, 6013–6020 (1999).
  CAS PubMed Google Scholar
• Pereira, M. A. et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 17, 1305–1311 (1996).
  CAS PubMed Google Scholar
• Hanif, R. et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52, 237–245 (1996).
  CAS PubMed Google Scholar
• Greenlee, R. T., Murray, T., Bolden, S. & Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin. 50, 7–33 (2000).
  CAS PubMed Google Scholar